Revefenacin is a novel, long-acting, non-selective muscarinic antagonist (LAMA) indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It acts by blocking M₃ receptors on airway smooth muscle. This blockade inhibits acetylcholine-induced bronchoconstriction, resulting in bronchodilation.
GMP DMF
